Psychedelics Research

A pioneering study from the Centre for Psychedelic Research at Imperial College London has revealed that psychedelics, such as magic mushrooms and LSD, can significantly improve sexual function for weeks or even months after the experience. Published in Nature Scientific Reports, this study is the...

As interest in psychedelic medicine grows, researchers are increasingly turning to natural substances like ayahuasca to explore their potential in treating mental health disorders. A recent review by researchers at the University of São Paulo sheds light on how ayahuasca – a traditional...

Veterans Affairs (VA) has announced a $1.5 million grant to study MDMA-assisted therapy for veterans with PTSD and alcohol use disorder, marking the first VA-funded psychedelic research in over 50 years. In January 2024, the VA first revealed plans to fund studies on the use of psychedelic...

The Yale Center for the Science of Cannabis and Cannabinoids, YC-SCAN², recently announced that it has awarded more than $600,000 in grants to 14 researchers from the Yale School of Medicine for innovative projects on the impact of cannabis and cannabinoids on neurodevelopment and mental health....

A recent study published in Scientific Reports explores the strategies individuals use to navigate challenging psychedelic experiences and how these responses relate to emotional breakthroughs. Researchers from University College London conducted a mixed-methods investigation, combining qualitative...

A 2,000-year-old Egyptian mug, known as a Bes mug, was used to consume a potent concoction of psychedelic substances, alcohol and human bodily fluids, according to new research. The study, published in Scientific Reports, utilized advanced chemical and DNA analysis to uncover the complex...

Georgia lawmakers are exploring the potential of psychedelics in treating veterans' mental health challenges, marking a significant shift in the state's traditionally conservative stance on drug policy. As Medical Xpress reported, a bipartisan panel has recommended allocating up to $5 million to...

In a rarely seen legal battle unfolding in a DEA courtroom in Arlington, Virginia, the future of two key psychedelic research compounds, DOI and DOC, hangs in the balance. The DEA's move to classify the substances as Schedule I drugs has sparked fierce resistance from researchers, neuroscientists...

Tryptamine Therapeutics Ltd (OTC:TYPTF) has announced that its lead asset, TRP-8803, a psilocin-based IV infusion, will progress to Phase 2 clinical trials following a successful Phase 1b study. TRP-8803 demonstrated significant advantages over oral psilocybin, including rapid onset, precise...

As interest in psychedelic-assisted therapies (PATs) grows, so does the need for clearer safety guidelines. Psychedelic treatments using substances like psilocybin, LSD, and MDMA are being explored for mental health issues like depression and PTSD, showing promising results. The FDA has granted...

Advanced AI has evolved over decades through research in computer science, neuroscience and machine learning. Early AI was rule-based, but breakthroughs in data processing, neural networks and deep learning have enhanced its ability to recognize patterns and learn from experience. With advances in...

Atai Life Sciences (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on mental health innovation, announced its third-quarter 2024 financial results Wednesday as well as updates on its clinical and corporate strategies. With notable advancements in its investigational programs, the...

Recent innovations in psychedelics research are laying the groundwork for a potential breakthrough in mental health treatments. The focus is on three new compounds patented by CaaMTech, Inc., designed to address the limitations of traditional psychedelics such as psilocybin and psilocin. According...

A study published in the Journal of Psychopharmacology has found that feelings of relaxation, rather than mystical experiences are the strongest predictor of positive outcomes in psychedelic-assisted therapy for treatment-resistant psychiatric disorders. Led by Gregor Hasler at Switzerland’s...

In a pioneering study funded by the UK Government, researchers at Imperial College London are set to examine the potential of psilocybin-assisted therapy to treat opioid addiction. As Leafie reported, this marks the first time that the UK government has backed research into using psilocybin for...